Cyanoacrylate adhesive embolization using the VenaSeal Sapheon Closure System (Venaseal) of the incompetent great saphenous veins offers several advantages over endothermal ablation including not requiring tumescent anasthaesia and use of compression stockings after the intervention. Endothermal ablation can also cause paresthesia in 5–10% of patients
The third paper in the series, published online on 18 July 2014 in Catheterization & Cardiovascular Interventions, outlines recommendations for treating infrapopliteal, or arterial disease below the knee
Two-year data from a prospective, multicentre study suggest that endovascular therapy with stenting may be considered the preferred first-line treatment option for aortoiliac lesions, irrespectively of TASC lesion category
Biotronik has announced that the first patient has been enrolled in the investigator-initiated BIOLUX 4EVER trial. Given the positive results from each of the previous drug-eluting balloon and self-expanding stent trials, investigators were interested in exploring the combined use of the Pulsar-18 self-expanding stent and Passeo-18 Lux drug-eluting balloon to see if the outcome could be improved further. BIOLUX 4EVER will follow the study design of the previously completed, investigator-initiated 4EVER trial, which examined the efficacy of the Pulsar-18 self-expanding stent in the treatment of superficial femoral artery lesions, but this time adding the Passeo-18 Lux drug-eluting balloon to the treatment. The study will enrol 120 patients treated with both products, with the primary endpoint of primary patency at 12 months
Since the NICE (National Institute for Health and Care Excellence) guidelines for the treatment of varicose veins was published in July 2013, endovenous thermal ablation has now “come of age”. Recommended as the first line treatment for symptomatic varicose veins of truncal origin, it is essential that every doctor practising varicose vein surgery has a good understanding of the principles of endovenous thermoablation
A study published in the Journal of the American Medical Association (JAMA) has found no difference in mortality rates between deep vein thrombosis patients treated with catheter-directed thrombolysis or anticoagulation alone. In the study, evidence of higher adverse events was noted in the catheter-directed thrombolysis group
Strict attention to technical details is the most important aspect of carotid endarterectomy. The ideal carotid endarterectomy technique should make sense intellectually, be easy to perform, be transferrable to other operators, be modifiable depending on the circumstances, and have superior outcomes and a low rate of recurrence. The neck positioning, exposure and dissection for all types of carotid reconstruction including endarterectomy with or without patch, bifurcation advancement and bypass are similar. The devil, so to say, is in the details with regards to handling of the plaque endpoint and method of arterial closure
Elective open surgical conversion for type Ia endoleak after endovascular aneurysm repair (EVAR) is not associated with increased morbidity or mortality compared with open juxtarenal aneurysm repair in appropriately selected patients, according to a study published in the Journal of Vascular Surgery. Open surgical conversion patients required longer procedure times and received more plasma transfusions
Cordis announced on 10 September the launch of its Incraft AAA Stent Graft System, an ultra-low profile device for use during endovascular aneurysm repair (EVAR) for patients suffering from infrarenal abdominal aortic aneurysms. The Incraft System is cleared for use and is now available in Europe and Canada. According to Cordis, the device is an advancement in the EVAR field and provides a new option for patients and physicians seeking a less invasive treatment approach for abdominal aortic aneurysms
Avinger has announced that John Pigott of Jobst Vascular Institute, Toledo, USA has enrolled the first patient in VISION. VISION is a global investigational device exemption (IDE) clinical trial, approved by the FDA, to evaluate Avinger’s Pantheris catheter for the treatment of peripheral artery disease
Data presented at the 26th World Congress of the International Union of Angiology (IUA), Sydney, Australia, highlights the benefit of ultrasound screening in detecting early signs of vascular disease in otherwise ‘low’ to ‘moderate’ risk asymptomatic individuals – with the potential to half the incidence of stroke and heart attacks
Endovascular repair of popliteal artery aneurysm provides successful aneurysm exclusion with good long-term patency, excellent limb salvage, and survival rates, according to a study published in the August 2014 edition of the European Journal of Vascular and Endovascular Surgery. At five years of follow-up, limb salvage was 98%, survival rate was 84% and mean sac volume shrinkage from 45.5mL to 23mL
Biotronik has announced the completion of patient enrolment in the superficial femoral artery (SFA) arm of its BIOFLEX-I clinical trial, an FDA-approved investigative device exemption (IDE) trial evaluating the use of self-expanding nitinol stents in treating peripheral artery disease. A total of 296 patients were successfully implanted with the Astron Pulsar and Pulsar-18 stents at 34 centres in the USA, Canada and Europe
Daisuke Kamoi, Nagoya Kyoritsu Hospital, Nagoya, Japan, reported on the first-in-man experience of angioscopy-guided chronic total occlusion techniques in peripheral arterial lesions at the EuroPCR congress (20–23 May, Paris, France). The system used in the study was the I-Light angioscopy system from iHeart Medical
Bristol‐Myers Squibb Company and Pfizer have announced that the European Commission has approved Eliquis (apixaban) for the treatment of deep vein thrombosis and pulmonary embolism, and the prevention of recurrent deep vein thrombosis and pulmonary embolism in adults. The European Commission approval applies to all European Union (EU) member states as well as Iceland and Norway. This approval broadens the clinical use for apixaban which is also approved for use in the EU for the prevention of venous thromboembolism (VTE) in adults who have undergone elective total hip or knee replacement surgery, and the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos